Action on Smoking and Health
America's FIRST Antismoking Organization
- Why Join NOW
Everything About Smoking and
Health and Nonsmokers' Rights
|
Action on Smoking
and Health
A National Legal-Action Antismoking Organization
Entirely Supported by Tax-Deductible
Contributions
Learn How You Can Protect Yourself and Your Loved Ones
From the Deadly Dangers of Even Small Amounts of Smoke
|
|
The P53 Tumour Suppressor Gene and the Tobacco Industry: Research, Debate, and
Conflict of Interest
By Asaf Bitton, Mark D Neuman, Joaquin Barnoya, Stanton A Glantz Volume 365, Number 9455 15 January 2005
Mutations in the p53 tumour suppressor gene lead to uncontrolled cell division
and are found in over 50% of all human tumours, including 60% of lung cancers.
Research published in 1996 by Denissenko and colleagues demonstrated patterned
in-vitro mutagenic effects on p53 of benzo[a]pyrene, a carcinogen present in
tobacco smoke. We investigated the tobacco industry's response to p53 research
linking smoking to cancer. We searched online tobacco document archives,
including the Legacy Tobacco Documents Library and Tobacco Documents Online, and
archives maintained by tobacco companies such as Philip Morris and R J Reynolds.
Documents were also obtained from the British American Tobacco Company
depository in Guildford, UK. Informal correspondence was carried out with
scientists, lawyers, and tobacco control experts in the USA and Europe. We found
that executives and scientists at the highest levels of the tobacco industry
anticipated and carefully monitored p53 research. The tobacco industry's own
scientists conducted research which appeared to cast doubt on the link between
smoking and p53 mutations. Researchers and a journal editor with tobacco
industry ties participated in the publication of this research in a
peer-reviewed journal without clear disclosure of their tobacco industry links.
Tobacco industry responses to research linking smoking to carcinogenic p53
mutations mirror prior industry efforts to challenge the science linking smoking
and lung cancer. The extent of tobacco industry involvement in p53 research and
the potential conflict of interest discussed here demonstrate the need for
consistent standards for the disclosure and evaluation of such potential
conflicts in biomedical research.
footer
Presented as a public service by Action
on Smoking and Health (ASH)
2013 H Street, N.W., Wash., DC 20006, Tel: (202) 659-4310
ASH, founded in 1968, is the national legal-action
antismoking and nonsmokers' rights organization which helped ban
cigarette commercials, started the modern nonsmokers' rights movement,
pioneered using legal action against smoking, developed novel legal
theories to protect children from tobacco smoke at home and in cars,
get lower health insurance rates for nonsmokers, fought tobacco
subsidies, and much much more.
ASH is
entirely supported by tax-deductible
contributions.
Material on this page may be freely reproduced, distributed, and
circulated,
but please credit ASH, and include ASH's web address: http://ash.org
